Dr. Warnock is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
619 19th St S
Birmingham, AL 35233Phone+1 205-934-6600
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 1971 - 1973- University of California (San Francisco)Internship, Internal Medicine, 1970 - 1971
- University of California San Francisco School of MedicineClass of 1970
Certifications & Licensure
CA State Medical License 1971 - Present
AL State Medical License 1989 - 2025- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1983
Clinical Trials
- Antiproteinuric Agents and Fabry Disease Start of enrollment: 2001 Jan 01
- The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study Start of enrollment: 2007 Mar 01
- Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease Start of enrollment: 2011 Feb 02
Publications & Presentations
PubMed
- 15 citationsHead-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised p...Eric L Wallace, Ozlem Goker-Alpan, William R Wilcox, Myrl Holida, John Bernat
Journal of Medical Genetics. 2024-05-21 - Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from...David G Warnock, Eric L Wallace
Journal of Medical Genetics. 2024-05-21 - 3 citationsElucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease.Valeria Nikolaenko, David G Warnock, Kevin Mills, Wendy E Heywood
Human Molecular Genetics. 2023-07-20
Press Mentions
Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium(TM) 2020March 5th, 2020
Simple Test Detects Increased Risks in Patients with Acute Kidney InjuryJanuary 30th, 2015- Most People with Moderate Kidney Disease Have Medication-Resistant HypertensionJuly 18th, 2013
- Join now to see all
Grant Support
- Activated Sodium Channels In HypertensionNational Institute Of Diabetes And Digestive And Kidney Diseases1997–2000
- Na+ Reabsorption And H+ Ion Secretion Renal MechanismsNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1999
- Conference--Epithelial Sodium Channel Gene SuperfamilyNational Institute Of Diabetes And Digestive And Kidney Diseases1994
- Na/Ion Reabsorption And H/Ion Secretion Renal MechanismsNational Institute Of Diabetes And Digestive And Kidney Diseases1988–1994
- General Medicine B Study SectionCenter For Scientific Review1989–1991
- Mechanisms And Consequences Of Renal HypertensionNational Institute Of Diabetes And Digestive And Kidney Diseases1988–1991
- Na/Ion Reabsorption &H/Ion Secretion Renal MechanismsNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1988
- Satellite On Membrane Transport ProteinsNational Institute Of Diabetes And Digestive And Kidney Diseases1987
- Na/Ion Reabsorption &H/Ion Secretion Renal MechanismsNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
